Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives

Area of Science:

• Oncology
• Glycobiology
• Immunotherapy

Background:

• Aberrant glycosylation is a key feature of cancer, altering tumor behavior and offering potential therapeutic targets.
• Glycans can be developed into clinical biomarkers and targeted for cancer intervention.
• Tumor-associated carbohydrate antigens (TACAs) arise from aberrant glycosylation, enabling selective cancer targeting.

Purpose of the Study:

• To review strategies for cancer immunotherapy targeting TACAs.
• To analyze antibody developments, vaccine production, and CAR-T cell generation for TACA-based therapies.
• To present results from clinical trials evaluating antitumor mechanisms against TACAs.

Main Methods:

• Review of literature on TACA-targeting cancer immunotherapies.
• Analysis of antibody development, vaccine strategies, and CAR-T cell therapies.
• Examination of clinical trial data for antitumor effects and technological advancements.

Main Results:

• Several TACAs, including truncated O-glycans, gangliosides, globo-serie glycans, Lewis antigens, and polysialic acid, are well-characterized targets.
• Approved immunotherapies, such as anti-GD2 antibodies, demonstrate the clinical utility of TACA targeting.
• Clinical trials show promising antitumor mechanisms and outcomes for various TACA-targeted approaches.

Conclusions:

• Targeting TACAs represents a significant strategy in cancer immunotherapy.
• Advancements in technology are expanding the possibilities for cancer control through TACA-targeted therapies.
• Further research and clinical trials are essential to fully realize the potential of TACA-based cancer treatments.